ImmunoGen Inc. (IMGN) announced Tuesday that it has completed patient enrollment in the first stage of its NORTH two-stage Phase II trial. The NORTH trial is assessing the Company's IMGN901 product candidate for first-line treatment of extensive disease small-cell lung cancer or SCLC. Attaining this milestone enables the findings from the planned interim analysis of PFS at 6 months to be available in 2H2013.
According to the company, the NORTH trial is designed to assess whether IMGN901 provides a clinically meaningful benefit when used in conjunction with a standard-of-care for this cancer, etoposide plus carboplatin (E/C). Patients with newly diagnosed extensive disease SCLC enrolled in the trial are randomized, two-to-one, to treatment either with IMGN901 plus E/C or with E/C alone.
While the NORTH trial is designed to include a total of 120 patients, its two-stage design specifies that an analysis of PFS at six months is to be performed with the first 39 evaluable patients randomized to the IMGN901 plus E/C treatment arm. Patient enrollment of this cohort of patients - and the corresponding 20 patients in the E/C alone arm - has now been completed. These patients will now be followed for the interim analysis while patient enrollment continues.
The 120-patient NORTH trial is designed to evaluate the efficacy and safety of IMGN901 for first-line treatment of extensive disease SCLC. All patients enrolled are provided with up to six cycles of E/C, standard-of-care for this cancer. Two-thirds of the patients enrolled are randomized to also receive IMGN901. These patients can elect to remain on IMGN901, as monotherapy, after completion of the E/C cycles if benefiting from treatment.
The primary endpoint of the NORTH trial is progression-free survival or PFS. Secondary endpoints include PFS at 6 months, overall survival at 12 months, time to progression, overall survival, and overall response rate.
IMGN901 was developed by ImmunoGen to target and kill CD56-positive cancer cells. CD56 is expressed on virtually all cases of SCLC. It is also expressed on a variety of other cancers including Merkel cell carcinoma and many cases of multiple myeloma.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.